Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study

ABSTRACT Properdin is an endogenous positive regulator of the complement alternative pathway (AP). Tarperprumig (ALXN1820), a novel humanized bispecific antibody, binds properdin and albumin and is being developed to treat complement‐mediated diseases. This phase I, randomized, double‐blind, placebo...

Full description

Saved in:
Bibliographic Details
Main Authors: Avner Sandhu, Tong Shen, Paz Martin Herrero, Chao‐Xing Yuan, Samirah Qureshi, Xiaoyu Jiang, Ye Sheng, Christoph Gasteyger, Yang Dai
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Science
Subjects:
pharmacodynamics
pharmacokinetics
phase I
safety
Online Access:https://doi.org/10.1111/cts.70190
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items